Collagenase clostridium histolyticum is a recognised non-surgical management for Peyronie's disease, licensed for use in the UK for patients with a palpable plaque and a curvature deformity of at least 30°.
Peyronie's disease (PD) is a common condition which results in penile curvature making sexual intercourse difficult or impossible. Collagenase clostridium histolyticum (CCH) is the first licensed drug for the treatment of PD and is indicated in patients with palpable plaque and curvature deformity of at least 30° of curvature.
To compare the efficacy and safety of a combined treatment of percutaneous needle tunnelling (PNT) and a modified collagenase Clostridium histolyticum (CCH) protocol (PNT/CCH) vs the modified protocol alone (CCH) in the treatment of Peyronie's disease (PD).
The effectiveness of phosphodiesterase type 5 (PDE5) inhibitors over the conservative management of Peyronie's disease (PD) has been widely questioned.
To determine the role of sildenafil 25 mg film formulation twice a day (S25 b.
Login to update email address, newsletter preferences and use bookmarks.